MAP2K7 and cutaneous melanoma: More recent trials including Flaherty et al,14 the COMBI-d study (Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma),16 the COMBI-v study (Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma),22 coBRIM trial (Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma),55 and COLUMBUS study (Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma)56 all included echocardiography at baseline, after 4 weeks, and at 12-weekly intervals thereafter.